

APPENDICES

INITIAL DECLARATIONS

APPENDIX A

[INFORMATION TO BE PROVIDED IN DECLARATIONS OF PAST BIOLOGICAL AND TOXIN OFFENSIVE AND/OR DEFENSIVE RESEARCH AND DEVELOPMENT PROGRAMMES]¹⁶²

1. Date of entry into force of the Convention for the State Party.
2. Past offensive biological research and development programmes.
 - (a) [Yes / No] [Existed / did not exist].
 - (b) Period(s) of activities.
 - (c) Summary of the research and development activities indicating whether work was [performed concerning] [done on] production, testing and evaluation, weaponization and stockpiling of biological agents, [whether there was a programme concerned with] the destruction [programme] of such agents and weapons, and [whether] other related research [was carried out].
3. Past defensive biological research and development programmes.
 - (a) [Yes / No] [Existed / did not exist].
 - (b) Period(s) of activities.
 - (c) Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, [toxinology,] [toxicology,] physical protection, decontamination, and other related research, with location, if possible.]

[PAST BIO-OFFENCE FACILITY]¹⁶³

162. The text in Appendix A has yet to be discussed.

163. This section reproduces format 2 of BWC/AD HOC GROUP/WP.318.

For each facility complete one form. Information to be provided for column 1-6 and 8-13 from 17 June 1925.

GENERAL INFORMATION

1. Name and postal address:
2. Location:
3. Scale map:
4. Owner(s):
5. Operator(s):
6. Years of operation since 17 June 1925:
7. Was the facility under operation before 17 June 1925? If so, indicate the date of establishment of the facility:
8. The type of work that was undertaken in this facility. If yes, relevant agents/toxins.
 - (a) Production of biological agent/toxin:
 - (b) Testing and evaluation:
 - (c) Studies on pathogenicity/virulence:
 - (d) Weaponization:
 - (e) Environmental stability studies on microbes:
 - (f) Stockpiling of agents and their quantity:
 - (g) Aerobiology studies:
 - (h) Vector biology studies including vector transmission:
 - (i) Molecular biology:
 - (j) Others (specify):
9. If agents/toxins were produced.

Cumulative amount of agents/toxin produced since 17 June 1925 for each agent/toxin (cumulative):

10. Present status of availability of the agent/toxin:
11. If agent/toxin was destroyed, how and when was it destroyed?
12. Floor area of maximum containment facility constructed for bio-offence purpose:
13. What is the present work carried out in the facility, if it is in use?
14. Method of destruction of the facility and the date of destruction:
15. The present status of the data, video recordings, etc. obtained when the facility was in operation:

PAST BIODEFENCE FACILITY¹⁶⁴

For each facility complete one form. Crucial starting date is 17 June 1925.

GENERAL INFORMATION

1. Name and postal address:
2. Location:
3. Scale map:
4. Owner(s):
5. Operator(s):
6. Years of operation since 17 June 1925:
7. Was the facility under operation before 17 June 1925? If so, indicate the date of establishment of the facility:
8. Description of the type of work that was undertaken:

	Relevant agent/toxin	Name/type	Development	Production	Evaluation	Quantity, if applicable	Year
Vaccine							
Plant inoculant							
Pharma-							

164. This section reproduces format 3 of BWC/AD HOC GROUP/WP.318.

	Relevant agent/toxin	Name/type	Development	Production	Evaluation	Quantity, if applicable	Year
ceutical product							
Diagnostic reagent							
Other products (specify)							

9. Was the facility used for any of the following?

	Yes / No	If yes, relevant agent/toxin	Done with animals/plants/humans
Toxicity evaluation			
Protection/detection/decontamination			
Vector biology studies			
Evaluation of pathogenicity, virulence, etc.			
Aerobiology studies			
Detection/diagnostic studies			
Genetic modification			
Maintain culture collection/repository			
Stability studies of agents/toxins			
Microbial susceptibility/resistance studies			
Others			

10. Floor area of BL4 (maximum containment) facility constructed for biodefence purpose:

11. What is the present work carried out in the facility, if it is in use?

12. If not in use, when was the facility dismantled?]

¹⁶⁵[1. Name of State Party:

.....

2. Date of entry into force of the Convention for the State Party:

.....

3. Date of initial declaration:

.....

PART A

PAST OFFENSIVE PROGRAMMES

1. Existed / Did not exist.

2. Period(s) of activities:

.....

3. Indicate whether any research and development activities or other work on microbial or other biological agents or toxins were carried out for hostile purposes or for use in armed conflict on any of the following:

Production	YES / NO
Testing	YES / NO
Evaluation	YES / NO
Weaponization	YES / NO
Stockpiling	YES / NO
Other acquisition	YES / NO

165. The following reproduces parts of BWC/AD HOC GROUP/WP.334.

4. Give a summary of each subject indicated as “YES” in paragraph 3 above:

.....
.....
.....

5. Indicate whether any research and development activities or other work was carried out on equipment or means of delivery for microbial or other biological agents or toxins for hostile purposes or for use in armed conflict, on any of the following:

Production	YES / NO
Testing	YES / NO
Evaluation	YES / NO
Stockpiling	YES / NO
Other acquisition	YES / NO

6. Give a summary of each subject indicated as “YES” in paragraph 5 above:

.....
.....
.....

7. Have any microbial or other biological agents or toxins ever been used for hostile purposes or in armed conflict?

YES / NO

8. If “YES” in paragraph 7, give a summary of each case indicating the agent(s), date(s) and place(s):

.....
.....
.....

9. List all facilities that participated in the programme and indicate which had been destroyed when and how it was done. Describe what was done with all the facilities that were not destroyed:

.....
.....
.....

10. List all test ranges used in the programme and give a description including dates of the dismantling or conversion of each:

.....
.....
.....

11. Indicate what all the converted facilities and test ranges are presently being used for:

.....
.....
.....

12. List all microbial or other biological agents or toxins studied, worked on, produced, stockpiled or weaponized:

.....
.....
.....

13. Indicate which agents listed in paragraph 12 above were destroyed, how, where and when it was done. Give a summary of what was done with those not destroyed:

.....
.....
.....

14. Give a summary of the destruction or conversion of the equipment described in paragraph 6 above:

.....
.....
.....

PART B

PAST DEFENSIVE PROGRAMMES

1. Existed / Did not exist.

2. Period(s) of activities:

.....

3. Give a summary of the general objectives of the programme, whether any research and development, testing and evaluation or production was done:

.....
.....
.....

4. Indicate whether any research and development or other work was conducted in the following areas:

	Research and development	Evaluation	Production
Prophylaxis			
Studies on pathogenicity			
Diagnostic techniques			
Aerobiology			
Detection			
Treatment			
Toxicology/toxinology			
Physical protection			
Decontamination			
Other related research			

5. Give a summary of each subject indicated in paragraph 4 above:

.....
.....
.....

6. Describe the principle objectives of any production or other acquisition activities for equipment or other items as part of the programme:

.....
.....
.....

7. List all microbial or other biological agents or toxins studied, worked on or produced as part of the programme:

.....
.....
.....

8. List all facilities which participated in the programme and indicate which are still involved in a present programme, if any:

.....
.....
.....]

ANNUAL DECLARATIONS

APPENDIX B

[INFORMATION TO BE PROVIDED IN DECLARATIONS OF [BIOLOGICAL] DEFENCE PROGRAMMES [AGAINST BIOLOGICAL WEAPONS]¹⁶⁶

1. [State] [Give a general description of] the objectives [and funding] of the programme and summarize the principal research, development, testing, production and evaluation [give a general description of the objectives and main elements of] activities [conducted in the programme] [carried out]. Areas to be [addressed] [covered] shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, [toxinology,] [toxicology,] physical protection, decontamination and other related research.
2. State:
 - (a) The total funding for the programme and its sources [(military, government, private);]
 - [(b) The total number of staff employed, including those contracted for less than six months;
 - (c) Details in the following categories:
 - (i) Military: scientists, technicians, engineers, medical, weapons experts, support and administrative;
 - (ii) Civilian: scientists, technicians, engineers, medical, support and administrative;
 - (d) The discipline of the scientific and engineering staff;
 - (e) All [listed] agents they keep and work with;
 - (f) Production of and stockpiling of [listed] agents in the programme including amounts of each [listed] agent;
 - (g) All [listed] agents on which genetic modification is being done.]

166. The text in Appendix B has yet to be discussed.

3. Are aspects of this programme conducted under contract with industry, academic institutions or in other non-defence facilities?

Yes / No

4. If yes, what proportion of the total funds for the programme is [expended in] [devoted to] these contracted or other facilities?
5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.
6. Provide a diagram of the organization[al structure of the programme] and the reporting [relationships] [structure of the programme] (include individual facilities participating in the programme).
7. Provide a declaration in accordance with Appendix C for each facility [both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence [research and development] programme, within the territory of the [reporting] State [Party], or under its jurisdiction or control anywhere] [which participates in the biological weapon protection programme and carrying out work on any microorganisms or toxins, as well as materials imitating their properties].]

¹⁶⁷[INFORMATION TO BE PROVIDED IN DECLARATIONS
OF CURRENT DEFENSIVE PROGRAMMES

1. Name of State Party:

.....

2. Reporting period

This declaration covers the calendar year:

.....

3. Give a general description of the objectives of the programme:

.....
.....
.....

167. The following reproduces parts of BWC/AD HOC GROUP/WP.325.

4. Give the organizational structure of the programme and its reporting relationships:

.....
.....
.....

5. Indicate which research and development activities were involved and give a summary of those indicated:

Prophylaxis	YES / NO
Pathogenicity and virulence	YES / NO
Diagnostic techniques	YES / NO
Aerobiology	YES / NO
Medical treatment	YES / NO
Toxinology/toxicology	YES / NO
Detection	YES / NO
Physical protection	YES / NO
Decontamination	YES / NO

6. What was the total funding of the programme?

.....

7. Name the sources of the funding:

.....
.....
.....

8. List all the biological agents and toxins on which research and development or any other work were conducted as part of the programme (you may indicate elements in the list which are confidential):

.....
.....
.....

9. List the names of all facilities involved in the programme and indicate the total number of person years of its technical or professional staff effort each facility devotes to the programme (you may indicate elements which are confidential):

.....
.....
.....

10. What is the publication policy for work conducted in the programme?

.....
.....
.....]

APPENDIX C

INFORMATION TO BE PROVIDED IN DECLARATIONS OF FACILITIES

[Guidelines for completing the declaration format

The declaration format requires information on facilities¹⁶⁸ that meet the criteria set out in one or more of the declaration triggers of the Protocol. Such facilities are referred to throughout the format as the “declared facility”.

The design of the format takes account of the differing sizes, complexities and scope of sites at which there are facilities satisfying one or more of the Protocol declaration triggers. It is recognized that in most cases the set of buildings, laboratories, structures and attributes that fall within the trigger specification, and that therefore are to be declared as the facility, may involve only a part of a site,¹⁶⁹ perhaps even only part of a building; in other words, the facility declarable under the Protocol may be co-located at a site with one or more other facilities that are not declarable. In other cases, however, the declared facility may consist of the entire site. The declaration format is designed to cover this range of possibilities.

In Part A, all declared facilities are required to answer questions relating to general information (section I) and to scientific and technical information (section II), regardless of the declaration trigger or triggers that apply at the particular facility. Additionally, in section III there are a number of questions which relate only to specific declaration triggers. Facilities triggered for declaration because they are part of the current biological defensive programme must also complete Part B.]

[PART A

Reporting period

This declaration covers the calendar year

The declaration trigger(s) that apply to the facility

Circle the declaration trigger(s) that apply to the facility. The facility being declared may satisfy a single declaration trigger or two or more triggers.

168. To be defined.

169. To be defined.

Facility in the current biological defensive programme

Vaccine production

[Maximum biological containment] [(BL4)] [laboratory] [facility]

[High biological containment] [(BL3)] [laboratory] [facility]

Work with listed agents and/or toxins

Other production

Other

I. GENERAL INFORMATION ABOUT THE DECLARED FACILITY

1. Name of the declared facility:

Name of site, if different:

2. Geographic coordinates, if known:

3. Street address:

4. Postal address:

5. Building details for the declared facility.

State, as appropriate, building name(s):

building number(s):

room number(s):

6. Provide a scale map of the locality, showing the declared facility.

7.¹⁷⁰ [Information on the entities that are the operators, owners and sources of funding of the declared facility.

Name(s) of operator(s) of the declared facility:

170. A view was expressed that additional detail about the nature of owners and/or operators of the declared facility should be requested in Part B on facilities in the current biological defensive programme.

Name(s) of owner(s) of the buildings of the declared facility, if different from the operator(s):

- (a) Indicate whether (any of) the operator(s) of the declared facility is/are part of the Ministry of Defence or the military:

Yes / No

- (b) If the owner(s) is/are different from the operator(s), indicate whether they/any of them are part of the Ministry of Defence or the military:

Yes / No

- (c) Indicate whether (any of) the major source(s) of funding of the declared facility is/are part of the Ministry of Defence or the military:

Yes / No

- (d) Indicate whether any attributes/activities that triggered the declaration were funded or supported by international organizations¹⁷¹:

Yes / No

- (e) Indicate whether any attributes/activities that triggered the declaration were funded or supported by other States:

Yes / No]

[Owner(s) of the facility:

- | | | | | | |
|--------------------------|---------------------------------------|--------------------------|--------|--------------------------|-----------|
| <input type="checkbox"/> | Ministry/Department/Agency of Defence | <input type="checkbox"/> | wholly | <input type="checkbox"/> | partially |
| <input type="checkbox"/> | Other government | <input type="checkbox"/> | wholly | <input type="checkbox"/> | partially |
| <input type="checkbox"/> | Non-government | <input type="checkbox"/> | wholly | <input type="checkbox"/> | partially |

If non-government, state name(s) of owner(s):

Operator(s) of the facility:

- | | | | | | |
|--------------------------|---------------------------------------|--------------------------|--------|--------------------------|-----------|
| <input type="checkbox"/> | Ministry/Department/Agency of Defence | <input type="checkbox"/> | wholly | <input type="checkbox"/> | partially |
| <input type="checkbox"/> | Other government | <input type="checkbox"/> | wholly | <input type="checkbox"/> | partially |
| <input type="checkbox"/> | Non-government | <input type="checkbox"/> | wholly | <input type="checkbox"/> | partially |

If non-government, state name(s) of operator(s):

171. To be defined.

[Commercial research, development, testing or evaluation;

Commercial production, including formulation or packaging;

University or other academic.]

II. SCIENTIFIC AND TECHNICAL INFORMATION ABOUT THE DECLARED FACILITY

All declared facilities are required to provide the following scientific and technical information, regardless of the declaration trigger or triggers relevant to the particular facility, in questions 10 - 19.

10. Indicate whether the declared facility was involved in work in any of the following subject areas. Such work may be, *inter alia*, research, development, testing, evaluation or production.

Exclusions: Work performed purely in order to set up standard operating procedures for equipment at the facility need not be declared.

- | | | |
|-----|--|----------|
| (a) | Vaccines ¹⁷³ | Yes / No |
| (b) | Other prophylaxis or therapy techniques for humans or animals | Yes / No |
| (c) | Plant inoculants | Yes / No |
| (d) | Plant biocontrol agents | Yes / No |
| (e) | Pathogenicity, virulence, infectivity or stability in the environment of microbial or other biological agents or toxins, or resistance to antimicrobial agents | Yes / No |
| (f) | Toxicity | Yes / No |
| (g) | Studies involving genetic modification | Yes / No |
| (h) | Aerobiology ¹⁷⁴ | Yes / No |
| (i) | Research, development, testing or evaluation of techniques for detection, identification or diagnosis | Yes / No |

173. To be defined.

174. To be defined.

- | | | |
|-----|---|----------|
| (j) | Physical protection techniques | Yes / No |
| (k) | Decontamination/disinfection techniques | Yes / No |
| (l) | Insect/pest control techniques for use in
agriculture/horticulture | Yes / No |

11. If the declared facility included laboratories designated as high biological containment¹⁷⁵ for human or animal pathogens, specify the floor area of the working areas, excluding shower areas, by indicating which range applies:

[up to 30 sq.m. 30-100 sq.m. over 100 sq.m.].

175. To be defined.

12. If the declared facility included room(s)/other enclosure(s) with quarantine for plants or plant pathogens,¹⁷⁶ specify the floor area of the working areas, excluding shower areas, by indicating which range applies:

[up to 30 sq.m. 30-100 sq.m. over 100 sq.m.].

13. Answer the questions about equipment at the declared facility, to be found in [Annex A, section II] [BWC/AD HOC GROUP/WP.286] [BWC/AD HOC GROUP/WP.318, format 4].

14. If the declared facility included chemical reactors, indicate:

- (a) For batch chemical reactors with an aggregate capacity over 100 litres, indicate which range applies:

[100 - 1,000 litres over 1,000 litres];

- (b) For (semi)continuous chemical reactors with a flow rate capable of exceeding 2 litres per hour, indicate which range applies:

[up to 20 litres per hour over 20 litres per hour].

15. If tissue culture media was used, indicate which range applies:

[up to 1,000 litres 1,000-10,000 litres over 10,000 litres].

16. If other complex culture media was used, indicate which range applies:

[up to 1,000 litres 1,000-10,000 litres over 10,000 litres].

17. If inoculated eggs were used to culture microorganisms, indicate which range applies:

[up to 1,000 eggs 1,000-10,000 eggs over 10,000 eggs].

18. Were there any areas at the facility which could only be entered by vaccinated personnel?

Yes / No

176. To be defined.

If Yes, indicate whether these areas are in

Laboratories

Production areas

Downstream processing, formulation or packaging areas

[Other areas (specify)]

List any vaccines that applied

.....
.....

[19. Were any pathogens or toxins transferred between the declared facility and any other areas on the same site?

Yes / No

If Yes, were any of these other areas

Laboratories	Yes / No
Animal houses	Yes / No
Production areas	Yes / No
Areas involved in downstream processing, formulation or packaging	Yes / No
Waste treatment areas	Yes / No
Areas involved in field testing or evaluation	Yes / No]

III. INFORMATION FOR SPECIFIC DECLARATION TRIGGERS

The following questions should be answered only when the trigger indicated applies.

20. Trigger: Vaccine production

If the declaration was triggered because of vaccine production, list the vaccines produced for distribution, sale, or public or general use:

.....
.....

21. Trigger: [Maximum biological containment] [(BL4)] [laboratory] [facility]

If the declaration was triggered by the presence of a [maximum biological containment] [(BL4)] [laboratory] [facility],

- (a) Indicate the total floor area of the working areas, excluding shower areas, by indicating which range applies:

[up to 30 sq.m. 30-100 sq.m. over 100 sq.m.].

- (b) Indicate whether work in these laboratories was carried out on

Human pathogens	Yes / No
Zoonotic pathogens	Yes / No
Other animal pathogens	Yes / No
Toxins	Yes / No
Plant pathogens	Yes / No

22. Trigger: Work with listed agents and/or toxins

If the declaration was triggered because of work with agents and/or toxins listed in Annex A, specify the agents worked with by annotating the corresponding entry in the list with an asterisk.

23. Trigger: Other production

If the declaration was triggered because of other production,

- (a) Indicate the type(s) of product produced. If more than one product applies, indicate with an asterisk which type constituted the major activity in terms of amount of product:

Medicine	[Antimicrobial]	Pesticides	Plant inoculants
Enzymes	Fine chemicals	Proteins other than enzymes	
Peptides or amino acids		Nucleic acids or genetic elements	
Microorganisms for use in biotransformation processes			
Other (specify)		

- (b) State if any of these products were produced for distribution, sale, or public or general use, either directly or after further processing, formulation or packaging:

Yes / No

- (c) State if any of these products were produced in areas protected by high biological containment:

Yes / No

24. Trigger: Plant quarantine areas

If the declaration was triggered by the presence of room(s)/other enclosure(s) with quarantine for plants or plant pathogens, specify the floor area by indicating:

[up to 30 sq.m. 31-100 sq.m. over 100 sq.m.].

25. Trigger: [High biological containment] [(BL3)] [laboratory] [facility]

...

26. Trigger: Other facilities

...]

[ALTERNATIVE TO PART A]¹⁷⁷

[I. GENERAL INFORMATION

1. Name of the facility:
2. Address:
3. Owner and operator of the facility:
4. Organization the facility is affiliated to:
5. Source of funding:

II. SUMMARY DESCRIPTION

1. Declaration trigger:
 - Vaccine production
 - High containment
 - ...
2. Objectives and main activities:

177. This section "Alternative to Part A" has yet to be discussed.

III. QUANTITATIVE DATA

1. Vaccine production: Yes No

	Vaccine	Quantity produced in previous year	Containment level
(i)
(ii)
(iii)
...

[For vaccine production facilities:

List of vaccines produced including average quantities produced the previous year.

For facilities producing vaccines and/or anatoxins to protect humans and animals against listed agents or toxins:

1. Name of facility.
2. Location (address and geographical location).
3. Types of vaccines produced.]

- [2. High containment: Yes No

- (i) Laboratory:

	Number of rooms	Working area (m ²)	Agents worked with and activity
BL3
BL4

- (ii) Production:

	Number of units	Working area (m ²)	Agents worked with and activity
Separation

Negative air pressure
-----------------------	-----	-----	-----

[For facilities with BL4 protected areas (Biosafety Level 4 (BL4) according to WHO classification) or P4 (according to WHO classification) or equivalent standard:

1. Name of facility.
2. Location (address and geographical location).
3. Ownership (government department or company).
4. Area of laboratories with Biosafety Level 4 (BL4), in square metres.
5. Indicate listed agents and toxins on which work is carried out.

List all the agents contained in the area, and production, stockpiling of, work with and genetic modification of agents contained in the area.

6. Indicate the main areas of activity in the facility (development of preventive agents and methods, observation, identification; genetic manipulation; aerobiology; toxinology; disinfection and other activities related to the purposes of the Convention).]

[3. Work with listed agents/toxins: Yes No

	Agent	Field of activity	Containment level	Consumption in previous year (g or ml)
(i)
(ii)
(iii)
...

[For facilities (except for diagnostic facilities) at which work is carried out on listed agents or toxins:

1. Name of facility.
2. Location (address and geographical location).

3. Ownership (government department or company).
4. Indicate the listed agents and toxins on which work is being carried out.
5. Main areas of activity (development of preventive agents and methods, observation, identification; genetic manipulation; aerobiology; toxinology; disinfection and other activities related to the purposes of the Convention).
6. The existence of premises with a BL4 level of biosafety.
7. Indicate all equipment present according to the list to be found in Annex A, section II.]

[4. Production equipment: Yes No

	Number	Total volume	Agents worked with	Containment level
Batch fermenter
Continuous fermenter

[For facilities that work with listed agents or toxins and have a production capability on site and other production facilities not necessarily working with listed agents or toxins:

List of products including average quantities produced the previous year.]

[5. Aerosol equipment: Yes No

(i) Aerosol chamber:

	Number	Volume	Agents worked with and activity	Containment level
Static
Dynamic
Explosive

(ii) Aerosol dispersal equipment:

--	--	--	--

	Number	Capacity	Agents worked with and activity
Powder dispersal
Liquid dispersal

[For facilities with equipment for production in the open air of aerosols with particle size not greater than 10 micrometres of any microorganisms or toxins, as well as materials that imitate their properties:

1. Name of facility.
2. Location (address and geographical location).
3. Ownership (government department or company).
4. List the microorganisms or toxins, as well as materials that imitate their properties, on which work is being carried out.
5. Indicate the main areas of activity of the facility (development of means and methods of prophylaxis, detection and isolation; genetic manipulation; aerobiology; toxinology; disinfection and other activities related to the purposes of the Convention).]

[6. Genetic modification activity: Yes No

	Agent or toxin concerned	Activity	Containment level
(i)
(ii)
(iii)
...

[OTHER FACILITIES¹⁷⁸

GENERAL INFORMATION

178. This section reproduces format 4 of BWC/AD HOC GROUP/WP.318.

1. Name and postal address:
2. Location:
3. Scale map:
4. Owner:
5. Operator:
6. Source of funding with proportion of each funding:
7. Staff resources:
8. General description of type of work in the facility as a whole:

SCIENTIFIC AND TECHNICAL INFORMATION

1. What is the area occupied for BL4/BL3 (working with listed agent/toxin)?
2. Full details for the following equipment:

Type of equipment	Capacity/size	Subtype (if applicable)	Number
Fermenters/bioreactors			
Separators*			
Freeze drying equipments			
Cell disruption equipments			
Aerosol chambers			
Biosafety hoods			
Isolators			
Self-sterilizable centrifuges			
Liquid nitrogen containers			
Ultra-deep freezers (-70°C or below)			
* Centrifugal, plate press filter, cross flow or tangential etc.			

3. Is the facility used for any of the following purposes?

	Type/name	Develop- ment Yes / No	Production Yes / No	Evaluation Yes / No	Annual quantity, if applicable
(a)	Microbial Agent/Toxin				
(b)	Vaccine				
(c)	Plant inoculant				
(d)	Pharmaceutical/ medical product				
(e)	Diagnostic reagent				
(f)	Other products (specify)				

4. Is the facility put to use for any of the following?

- | | | |
|-----|--|----------|
| (a) | Toxicity evaluation | Yes / No |
| (b) | Physical protection, detection/decontamination | Yes / No |
| (c) | Vector biology studies | Yes / No |
| (d) | Evaluation of pathogenicity, virulence, stability in the environment, etc. | Yes / No |
| (e) | Aerobiology studies | Yes / No |
| (f) | Studies involving genetic modification | Yes / No |
| (g) | Diagnostics | Yes / No |
| (h) | Maintain culture collection/repository | Yes / No |
| (i) | Microbial susceptibility/resistance studies | Yes / No |
| (j) | Others | |

5. Are there any areas which can be entered only by personnel who have been vaccinated:

Yes / No

If yes, specify the type of vaccines and area.]

[PART B¹⁷⁹

ADDITIONAL INFORMATION FOR FACILITIES DECLARED AS PART OF THE
CURRENT BIOLOGICAL DEFENSIVE PROGRAMME

The following additional information is required for facilities triggered for declaration because they are part of the current biological defensive programme.

1. State the aims and objectives of the facility's work as part of the current biological defensive programme:

.....
.....
.....

2. Funding.

- (a) What are the funding levels for the current biological defensive programme work at the facility?

.....

- (b) If (parts of) this work is included in a joint work programme at the facility, for example in a work programme addressing both chemical and biological defence issues, indicate the approximate proportion of this joint work that relates to the current biological defensive programme:

..... per cent

3. Briefly describe the biological defensive programme work at the facility, summarizing any experimental studies involving microbial or other biological agents, or toxins on the following topics: prophylaxis, pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment or toxinology for the purpose of protecting or defending humans, animals or plants against the use of microbial or other biological agents, or toxins for hostile purposes or in armed conflict:

.....
.....
.....

179. These sections "Part B" and "Alternative to Part B" were not discussed during the twelfth session of the Ad Hoc Group. It was agreed to discuss it at the thirteenth session.

.....
.....

(continue on separate pages if necessary)

4. Does the facility include laboratory activities involved in routine medical/veterinary/phytopathology diagnosis?

Yes / No

5. What is the publication policy for the current biological defensive programme work at the facility?

.....
.....

6. List the papers published during the reporting year in scientific/technical/medical/veterinary journals or in conference proceedings:

.....
.....
.....]

[ALTERNATIVE TO PART B]¹⁸⁰

[INFORMATION TO BE PROVIDED IN DECLARATIONS OF [BIOLOGICAL DEFENCE FACILITIES] [FACILITIES TAKING PART IN [BIOLOGICAL] DEFENCE PROGRAMMES [AGAINST BIOLOGICAL WEAPONS]]

[In shared facilities, provide the following information for the biological defence research and development portion only.]

[I. GENERAL INFORMATION

1. Name of the facility:]

- [1. What is the name of the facility?]

- [2. Address:]

- [2. Where is it located (include both address and geographical location)?]

- [3. Owner and operator of the facility:

4. Organization the facility is affiliated to:

180. Ibid.

5. Sources of funding (annual).

Total:

	Ministry of Defence	Other governmental department	Private	Other
Amount				

6. Distribution of funding (annual).

	Research	Development	Testing	Production	Other
Amount					

]

[(f) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

(g) What are the funding levels for the following programme areas?

Research

Development

Test and evaluation]

[7. Personnel.

(a) Total number:

(b) Division.

(i) Military:

(ii) Civilian:

(iii) Contract staff (more than 6 months per year):

.....

(c) Division of personnel by category.

(i) Scientists:

- (ii) Engineers:
- (iii) Technicians:
- (iv) Administrative and support staff:
.....

[4. (d) Scientific disciplines represented in the scientific/engineering staff:]
The organizational structure of each facility.

- (a) Total number of personnel:
- (b) Division of personnel.
 - (i) Military:
 - (ii) Civilian:
- (c) Division of personnel by category.
 - (i) Scientists:
 - (ii) Engineers:
 - (iii) Technicians:
 - (iv) Administrative and support staff:
.....

- (d) List the scientific disciplines represented in the scientific/engineering staff:
- (e) Are contractor staff working in the facility? If so, provide an approximate number:]

[II. SCIENTIFIC AND TECHNICAL ACTIVITIES

1. General description (including purposes and objectives):]

[5. Briefly describe the [biological defence work] [the work carried out at the facility as part of the [biological] defence programme [against biological weapons]] including type(s) of microorganisms¹⁸¹ and/or toxins studied, as well as outdoor studies of biological aerosols [any

181. Including viruses and prions.

work with biological aerosols, including open air test ranges, aerosolization activities, work with test chambers]:]

[2. Activities: mark research, development, testing, production or none by entering R (Research), D (Development), T (Testing), P (Production) or N (None) in the brackets:

- (a) Detection, identification, and diagnosis ()
- (b) Decontamination, disinfection, and pest control ()
- (c) Prophylaxis: specific ()
non_specific ()
- (d) Physical protection ()
- (e) Treatment ()
- (f) Characteristics of biological agents and toxins ()
pathogenicity/virulence ()
stability ()
- (g) Reproducibility of biological agents or toxins ()
- (h) Aerobiology ()
- (i) Genetic modification ()
- (j) Insect microbiology ()

3. Listed agents or toxins worked with:

	Name	Activity	Consumption in the previous year (g or ml)
(i)			
(ii)			
(iii)			

III. WORKING AREAS AND EQUIPMENT

1. Biosafety level.

(a) Laboratory.

BL3: _____ rooms, total floor area _____ m²

BL4: _____ rooms, total floor area _____ m²

(b) Production.

Separation: _____ units, total floor area _____ m²

Negative air pressure: _____ units, total floor area _____ m²]

[3. [Number of rooms and] floor area of laboratory areas by containment level.

BL2: _____ (m²) [_____ rooms]

BL3: _____ (m²) [_____ rooms]

BL4: _____ (m²) [_____ rooms]

or highest level of containment if none of the above:

_____ (m²) [_____ rooms]

Total laboratory floor area _____ (m²)]

[2. Aerobiology.

(a) Aerosol chamber.

(i) Static:

total number __, number: < 2 m³ __, 2 _ 20 m³ __, > 20 m³ __

(ii) Dynamic:

total number __, number: < 10 m³ __, 10 _ 200 m³ __, > 200 m³ __

(iii) Explosive:

total number __, number: < 10 m³ __, 10 _ 200 m³ __, > 200 m³ __

(b) Aerosol dispersal equipment.

(i) Powder aerosol dispersal: number __, capacity (g/min) __

(ii) Liquid aerosol dispersal: number __, capacity (ml/min) __

3. Genetic modification.

(a) Automatic DNA sequencing equipment: number ____

(b) DNA synthesizer equipment: number ____

4. Insect microbiology.

Insect rearing chamber: number __, total working area ____ m²

5. Production equipment:

(a) Fermentation equipment (bio_reactors).

(i) Batch fermenter:

total number: __, number: < 100 l __, 100 _ 1,000 l __, > 1,000 l __

(ii) Continuous fermenter:

total number: __, number: ≤ 50 l __, >50 l __]

[Aggregate fermenter capacity on site:]

[(b) Separator and concentrator.

(i) Continuous or semi_continuous separators:

total number: __, number: <100 l/hr __, 100 _ 1,000 l/hr __,
> 1,000 l/hr __

(ii) Batch separator:

total number: __, number: ≤ 100 l/batch __, $> 1,000$ l/batch __

(iii) Cross_flow tangential filtration equipment:

total number: __, number: < 5 m² __, 5 _ 10 m² __, > 10 m² __

(iv) Plate_press filter separator:

number: __

(c) Isolation and purification equipment.

(i) Cell disruption equipment:

total number: __, ≤ 10 l/hr __, > 10 l/hr __

(ii) Chromatography column:

number: __

- (d) Drying equipment.
- (i) Freeze_drying:
number: __, number with condenser capacity: ≤ 50 kg/d __,
> 50 kg/d __
- (ii) Spray_drying:
number: __, number with flow capacity: ≤ 5 l/hr __, > 5 l/hr __
- (iii) Drum_drying:
number: __
- (e) Other equipment.
- (i) Micro_encapsulation equipment:
number: __
- (ii) Milling equipment capable of milling to $<10\mu\text{m}$:
number: __]

[IV. LIST OF PAPERS PUBLISHED IN THE PREVIOUS YEAR]

- [(h) Briefly describe the publication policy of the facility:
- (i) Provide a list of publicly available papers and reports resulting from the work during the previous 12 months: (To include authors, titles and full references.)]

[The initial and subsequent annual declarations¹⁸² of facilities participating in the biological weapon protection programme and carrying out work on any microorganisms or toxins, as well as materials imitating their properties should include the following information:

1. Name.
2. Location.
3. Ownership (government department or company).

182. The initial declarations should comply with the agreed format for declarations. Subsequent declarations should contain only necessary refinements of the initial information or an indication that there are “no declarable changes”.

4. List of biological agents and toxins on which work is being carried out.
5. Main areas of activity (development of preventive agents and methods, observation, identification; genetic manipulation; aerobiology; toxinology; disinfection and other activities related to the purposes of the Convention.
6. The existence of premises with a BL4 level of biosafety.
7. The presence of types of key equipment.]]

[PRESENT BIODEFENCE FACILITY¹⁸³

Present biological defence facility. Complete one declaration form for each facility for the last calendar year.

GENERAL INFORMATION

In shared facilities, provide information (1-9) related to the biodefence programme only.

1. Name and postal address:
2. Location:
3. Scale map:
4. Owner:
5. Operator:
6. Source of funding with proportion of each funding:
7. Staff resources:

	Physicians	Scientists	Engineers	Others
Military personnel				
Civilian				
Contract employees who have worked for more than 6 months in the reporting calendar year				

183. This section reproduces format 1 of BWC/AD HOC GROUP/WP.318.

8. Division of scientists/engineers by category.

SCIENTISTS

	Military	Civilian	Contract*
Microbiologists			
Pathologists			
Molecular biologists			
Epidemiologists			
Entomologists			
Plant pathologists			
Others			
* Contract employees who have worked for more than 6 months in the reporting calendar year.			

ENGINEERS

	Military	Civilian	Contract*
Mechanical engineers			
Chemical engineers			
Electronics/instrumentation engineers			
Others			

9. (a) What is the size of the animal house facility and the number of animals (categorywise) used in this biodefence facility in the last 12 months?
- (b) What is the size of insect culture facility (if co-located)?
10. General description of type of work in the facility as a whole. Include also the connectivity with non-biodefence programmes. If the facilities for other programmes are co-located.

SCIENTIFIC AND TECHNICAL INFORMATION

1. Area occupied by: [Whether underground (UG) or above ground (AG)]

--	--	--

	Total area	No. of rooms
BL4		
BL3		
Total laboratory floor area		

2. Fill details for the following equipments if used:

Type of equipment	Size/capacity	Subtype	Where used BL4/ BL3/others
Fermentors/ bioreactors			
Separators*			
Freeze drying equipments			
Cell disruption equipments			
Aerosol chambers			
Biosafety hoods			
Isolators			
Self-sterilizable centrifuges			
Cryopreservation units			
Liquid nitrogen containers			
Ultra deepfreezers (below -70°C)			
* Centrifugal, plate press filter, cross or tangential flow etc.			

3. Description of the activity leading to production in each containment:

BL4

	Relevant agent/	Name/	Develop- ment	Pro- duction	Test/ Evaluation	Annual quantity

	toxin, if applicable	type	Yes / No	Yes / No	Yes / No	produced, if applicable
Microbial agent/toxin						
Vaccine/antitoxin						
Plant inoculant						
Pharmaceutical/ medical product						
Diagnostic reagent						
Other products (specify)						

BL3

Purpose microbiology/ toxin	Relevant agent/ toxin, if applicable	Name/ type	Development Yes / No	Production Yes / No	Test/ Evaluation Yes / No	Annual quantity produced, if applicable
Microbial agent/toxin						
Vaccine/antitoxin						
Plant inoculant						
Pharmaceutical/medical product						
Diagnostic reagents						
Other products (specify)						

4. Is the facility put to other use for any of the following (Yes / No).

	BL4	BL3	If yes, relevant agent/toxin	Done with plants/ animals/humans
Toxicity evaluation				
Physical protection/ detection/decontamination				
Vector biology studies				
Evaluation of pathogenicity, virulence, etc.				
Aerobiology studies				
Genetic modification				
Diagnostics, detection studies				
Maintain culture collection/ repository				
Stability studies of agents/ toxins				
Microbial susceptibility/ resistance studies				
Others				

5. Describe publication policy of the facility and provide reports/papers publicly made available in the last 12 months.]

[APPENDIX D¹⁸⁴

INFORMATION TO BE PROVIDED IN CURRENT BIOLOGICAL
DEFENCE LISTING FORMAT

Non-Governmental Facilities

1. Do you have a non-governmental facility or facilities that received government funds or resources to support, and that devoted more than ... person years of its technical or professional staff effort to research and development activities on prophylaxis, pathogenicity and virulence, diagnostic techniques, aerobiology, medical treatment, or toxinology/toxicology activities, and which directly protect or directly defend human, animals, or plants against the use of microbial or other biological agents and toxins for hostile purposes or in armed conflict?

___Yes

___No

2. If yes, provide the following information on each listed facility:

- Name of the non-governmental facility:
- Address:
- Postal address, if different than above:
- Estimate the number of person years of technical or professional staff effort devoted to the activities noted above:
- Estimate the monetary amount of government funding in the calendar year:
- Provide a brief description of the objective(s) of the work (ten lines or less):
- Estimate the duration of the contract or grant:

___ less than one year ___ 1 to 3 years ___ more than 3 years]

184. The following reproduces parts of BWC/AD HOC GROUP/WP.319.

[APPENDIX E¹⁸⁵

INFORMATION TO BE PROVIDED IN THE DECLARATION
OF IMPLEMENTATION OF ARTICLE X OF THE CONVENTION

1. A general description of the measures taken to facilitate the fullest possible exchange of equipment, materials and scientific and technological information for the use of the bacteriological (biological) agents, toxins for peaceful purposes.
2. A general description of the measures taken to the further development and application of scientific discoveries in the field of bacteriology (biology) for the prevention of disease or for other peaceful purposes.
3. A general description of the status of the implementation of Article X of the Convention.
4. Specific measures undertaken to review the existing national trade legislation or regulations, to promote transfers of bacteriological (biological) materials, equipment and technology for peaceful purposes.]

185. This appendix reproduces BWC/AD HOC GROUP/WP.350. It was not discussed during the thirteenth or fourteenth session of the Ad Hoc Group.

APPENDIX F

[LIST OF APPROVED INVESTIGATION/VISIT EQUIPMENT

	Description	Notes
	SAMPLING AND IDENTIFICATION EQUIPMENT¹⁸⁶	
1	Transport media	
2	Sample containers	
3	Shipping containers	
4	Preserving media and fixatives (i.e. formalin, alcohol, silica gel)	
5	Forceps (various sizes)	
6	Post mortem sets	
7	Syringes and needles for blood samples	
8	Thermometers and probes	
9	Incinerator and disinfectant tanks/sprays	
10	Biohazard bench, glove box	
11	Gas burners	
12	Microscopes, stains and slides	
13	Culture media	
14	Autoclave/pressure cooker	
15	Incubator and anaerobic equipment	
16	Freezer: -70°C best	
17	Refrigerator	
18	Portable PH metre/millivolt metre with ion-specific electrodes	
19	Glucose analyser	
20	Dissolved oxygen metre	
21	Pruning shears	

186. The list of sampling equipment will depend on whether analyses will be done on-site or off-site.

	Description	Notes
22	Spades	
23	Soil augers	
24	Sampling equipment for: Air samples Surface samples Fluid samples other than water	
25	Water sampling equipment	
26	Portable water pump	
27	Seals (fibre optic and packages)	
28	Seals (frangible, fractural, adhesive)	
29	Vacuum sealing equipment	
30	Tags/tie on/markers (permanent)	
31	Centrifuges	
32	Portable spectroscopic analyser	
33	Portable flow cytometers	
34	PCR equipment	
35	DNA sequencer	
36	Particle counter	
37	Electrophoretic apparatus	
38	Pipettes	
39	Freeze drying equipment (lyophilizers)	
40	Water baths	
41	Diagnostic kits	
42	Entomological equipment	
	PROTECTIVE EQUIPMENT	
1	Protective clothing	
2	Boots (disposable)	
3	Protective gloves with liners	

	Description	Notes
4	Protective masks (military type)	
5	Spare filter canisters (military)	
6	Spare filter canisters (industrial)	
7	Surgical gloves	
8	Safety goggles	
9	Leather work gloves	
10	Industrial safety helmet	
11	Hearing protection	
12	Cotton coveralls	
13	Disposable coveralls	
14	UV protective glasses	
15	Water bottle	
16	Flashlight explosion proof	
17	First aid kits (personal)	
18	Self-contained breathing apparatus (SCBA)	
19	Respirator (industrial/microbiological)	
20	Equipment bags	
21	Mask fit test kit	
22	Cooling vest	
23	Cold weather gear	
24	Safety lantern	
25	Safety shoes	
26	Flammability/explosive/air quality/monitor	
27	Mosquito nets	
28	Insect repellent	
29	Water filter kit	
	MEDICAL EQUIPMENT	
1	General first aid kit	
2	Patient monitoring equipment	

	Description	Notes
3	General medical examination equipment	
4	Mobile blood gas analyser	
5	Blood cell counter - Coulter counter	
6	Portable chemical pathology set	
	ADMINISTRATIVE EQUIPMENT	
1	Portable photo-copying machine	
2	Portable document scanner	
3	Portable document shredder	
4	Waterproof pens	
5	Tape measure (3 m, 30 m, 100 m)	
6	Callipers and steel ruler	
7	Maps	Geographic maps necessary for a specific field investigation procured for that investigation.
8	Graph paper, pencils and labels	
9	Calculator	
10	Computer (notebook) with printer/plotter and modem	Software to include geographical information.
11	Satellite link telephones	
12	Portable fax machines	
13	Exterior extension cords	
14	Secure voice telephone	
15	Short-range radios	
16	Electric plug-socket adaptors	
17	Portable over-head projector	
18	Image transmission equipment	This aspect needs further discussion.
	OTHER TECHNICAL EQUIPMENT	
1	Maintenance tool kit	

	Description	Notes
2	Equipment transport containers	
3	Global positioning system (GPS)	
4	Weighing equipment	
5	Polaroid-type camera with flash, zoom, macro lens systems and films	
6	35 mm camera with flash, zoom, macro lens systems and films	
7	Digital video camera - portable video player with tapes	
8	Audio (tape) recorder with tapes	
9	Binoculars	
10	Data scope	
11	Night-vision scope	
12	Magnifying glass	
13	Rechargeable batteries (Ni-Cd) and battery chargers	
14	Shoulder bag	
15	Tool belt	
16	Compass	
17	Thermochromic tape packages	
18	Electrical power generators	
19	Barometer, anemometer, hygrometer with recording attachments	For use in establishing background conditions which might influence survival of microorganisms.
20	Wet bulb globe thermometer	
21	[Chemical agent monitor]	
	NON-DESTRUCTIVE EVALUATION EQUIPMENT	
1	Portable X-ray equipment	
2	Ultrasonic pulse echo	

ANNEX II

INDICATIVE PROGRAMME OF WORK FOR THE FIFTEENTH SESSION ¹⁸⁷

(28 June - 23 July 1999)

First week: 28 June - 2 July 1999

	28 June	29 June	30 June	1 July	2 July
AM	AHG/CM	CM	CM	CM	LEG(_) PRE(_)
PM	ART.X	ART.X	ART.X	ART.X	NAT/ORG/ SEAT

Second week: 5 - 9 July 1999

	5 July	6 July	7 July	8 July	9 July
AM	CM	CM	CM	CM	CONF
PM	INV ANN	INV ANN	INV ANN	INV ANN	LEG/ORG/ SEAT

Third week: 12 - 16 July 1999

	12 July	13 July	14 July	15 July	16 July
AM	ART.X	DEF	DEF	DEF	DEF
PM	CM	CM	CM	CM	DEF

Fourth week: 19 - 23 July 1999

	19 July	20 July	21 July	22 July	23 July
AM	ART.X	ART.X	ART.X	NAT(_)/ CM(_)	CM
PM	DEF	DEF	DEF	DEF	DEF(_)/ AHG(_)

187. The present allocation of meetings on different issues is without prejudice to their allocation in the future.

AHG	-	Ad Hoc Group meetings
INF CONS	-	Informal consultations
CM	-	Measures to Promote Compliance (FOC)
INV ANN	-	Investigations Annex (FOC)
DEF	-	Definitions of Terms and Objective Criteria (FOC)
ART.X	-	Measures Related to Article X (FOC)
LEG	-	Legal Issues (FOC)
ORG	-	Organization/Implementational Arrangements
CONF	-	Confidentiality (FOC)
NAT	-	National Implementation and Assistance (FOC)
SEAT	-	Seat of the Organization (FOC)
PRE	-	Preamble (FOC)

ANNEX III

LIST OF DOCUMENTS SUBMITTED AT THE FOURTEENTH SESSION

<u>Document Symbol</u>	<u>Title</u>
BWC/AD HOC GROUP/WP.353	Working paper submitted by the Friend of the Chair on Measures to Promote Compliance - E. Consultation, clarification and cooperation
BWC/AD HOC GROUP/WP.354*	Working paper submitted by Japan - Proposed changes of text
BWC/AD HOC GROUP/WP.355	Working paper submitted by Japan - Access and conduct of investigations involving States other than the State Party to be investigated
BWC/AD HOC GROUP/WP.356	Working paper submitted by the Republic of Croatia - Proposed text for Article III - Declarations
BWC/AD HOC GROUP/WP.357	Working paper submitted by the United Kingdom of Great Britain and Northern Ireland - Field investigations and access to facilities and locations outside the original designated area(s) for investigations - Treaty text
BWC/AD HOC GROUP/WP.358	Working paper submitted by the United Kingdom of Great Britain and Northern Ireland - Voluntary visits
BWC/AD HOC GROUP/WP.359	Working paper submitted by South Africa - Proposed text for clarification visits
BWC/AD HOC GROUP/WP.360	Working paper submitted by South Africa - Proposed text for Annex B
BWC/AD HOC GROUP/WP.361	Working paper submitted by the Islamic Republic of Iran - Lessons to be learned from the OPCW
BWC/AD HOC GROUP/WP.362	Working paper submitted by the Netherlands and New Zealand - BWC Article X / Protocol Article VII

BWC/AD HOC GROUP/WP.363	Working paper submitted by Australia and the United Kingdom of Great Britain and Northern Ireland - Article VII - Proposals
BWC/AD HOC GROUP/WP.364	Working paper submitted by Australia - Preamble
BWC/AD HOC GROUP/WP.365	Working paper submitted by the Friend of the Chair on the Seat of the Organization - Draft questionnaire for the seat of the BWC Organization
BWC/AD HOC GROUP/FOC/15	Proposals for further consideration by the Friend of the Chair on Definitions of Terms and Objective Criteria
BWC/AD HOC GROUP/FOC/16	Proposals for further consideration by the Friend of the Chair on Seat of the Organization
BWC/AD HOC GROUP/FOC/17	Proposals for further consideration by the Friend of the Chair on Measures to Promote Compliance
BWC/AD HOC GROUP/FOC/18	Proposals for further consideration by the Friend of the Chair on Measures Related to Article X
BWC/AD HOC GROUP/L.43	Draft Procedural report of the Ad Hoc Group of the States Parties to the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction
BWC/AD HOC GROUP/L.44	Outcome of discussions by the Friend of the Chair on Investigations Annex
BWC/AD HOC GROUP/L.45	Outcome of discussions by the Friend of the Chair on Preamble

BWC/AD HOC GROUP/L.46	Outcome of discussions by the Friend of the Chair on Measures to Promote Compliance
BWC/AD HOC GROUP/L.47	Outcome of discussions by the Friend of the Chair on Measures Related to Article X
BWC/AD HOC GROUP/45 (Part I) and (Part II)	Procedural report of the Ad Hoc Group of the States Parties to the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction
BWC/AD HOC GROUP/INF.18	List of States Parties to the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction
BWC/AD HOC GROUP/INF.19 and Add.1	List of participants
